COMPARATIVE ANALYSIS OF DIFFERENT NEOADJUVANT CHEMOTHERAPY REGIMENS FOR TRIPLE-NEGATIVE BREAST CANCER

Background. Breast cancer is a heterogeneous disease with a variety of phenotypic forms. Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes characterized by high sensitivity to chemotherapy and early recurrence. Due to the lack of efficiency of standard therapeutic approaches, it appears extremely important to search for new regimens of neoadjuvant polychemotherapy (NAPCT). Objective: to assess the efficiency of different NAPCT regimens for treatment of stages T1N1–3 and T2–4N0–3 locally advanced TNBC and to compare the efficiency of eribulin and paclitaxel in NAPCT of TNBC.

Materials and methods. A randomized prospective study to evaluate the efficacy of TNBC treatment is being conducted in the N.N. Petrov National Medical Research Center of Oncology since October, 2015. The study included 61 patients with a median age of 45 years (range 31–76 years). Study participants were treated with 2 different NAPCT regimens: patients in the 1^st group received eribulin at a dose of 1.1 mg/m² on the days 1 and 8 of a 21-day cycle in combination with carboplatin AUC6, patients in the 2^nd group received paclitaxel at a dose of 80 mg/m² on the days 1 and 8 of a 21-day cycle in combination with carboplatin AUC6. Then all patients underwent surgery in different volume (radical mastectomy, organ-preserving surgery, reconstructive plastic surgery) with subsequent FAC adjuvant chemotherapy.

Results. So far, 61 patients have been randomized (further calculations are based on the number of operated patients: 24 in the 1^st group and 27 in the 2^nd group). During the preoperative stage, complete clinical regression was achieved in 11 patients from the 1^st group and 15 patients from the 2^nd group; partial clinical regression was observed in 13 and 12 patients in groups 1 and 2 respectively. We found that the therapeutic regimen with paclitaxel + carboplatin induced a higher rate of pathologic complete responses (ypCR). After NAPCT, 51 out of 61 patients (84 %) underwent surgical treatment. Pathomorphological examination showed that the frequency of pathologic complete response was 33 % (8 cases) in the 1^st group compared to 60 % (16 cases) in the 2^nd group. Five patients treated with eribulin + carboplatin developed distant metastases in bones, lungs, brain, postoperative scar and lymph nodes in the neck on average 4 months after surgery.

Conclusions. Higher rate of ypCR was observed in patients received paclitaxel + carboplatin.

1. Семиглазов В.Ф., Палтуев Р.М., Семиглазова Т.Ю. и др. Клинические рекомендации по диагностике и лечению рака молочной железы. М.: ИД «АБВ-пресс», 2013. 234 с. [Semiglazov V.F., Paltuev R.M., Semiglazova T.Yu. et al. Clinical guidelines for the diagnosis and treatment of breast cancer. Moscow: Publishing Center “ABV-press”, 2013. 234 p. (In Russ.)].

2. Манихас А.Г., Бабешкин Р.Н., Палтуев Р.М., Манихас Г.М. Место неоадъювантной химиотерапии трижды негативного рака молочной железы в Санкт-Петербургском городском клиническом онкологическом диспансере. Опухоли женской репродуктивной системы 2017;12:26–34. [Manikhas A.G., Babeshkin R.N., Paltuev R.M., Manikhas G.M. The role of neoadjuvant chemotherapy of triple negative breast cancer in the Saint Petersburg City Clinical Oncology Dispensary. Opukholi zhenskoy reproduktivnoy sistemy = Tumors of Female Reproductive System 2017;12:26–34. (In Russ.)].

3. Зикиряходжаев А.Д., Фролова М.А., Рассказова Е.А., Глазкова Е.В. Лечение тройного негативного подтипа рака молочной железы. Опухоли женской репродуктивной системы 2017;13(2):20–6. [Zakiryakhodzhaev A.D., Frolova M.A., Rasskazova E.A., Glazkova E.V. Treatment of triple-negative breast cancer. Opukholi zhenskoy reproduktivnoy sistemy = Tumors of Female Reproductive System 2017;13(2):20–6. (In Russ.)].

4. Okouneva T., Azarenko O., Wilson L. et al. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 2008;7(7):2003–11. DOI: 10.1158/1535-7163.MCT-08-0095.

5. Vahdat L.T., Pruitt B., Fabian C.J. et al. Phase II study of eribulin mesylate, a halichondrin В analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Clin Oncol 2009;27(18):2954–61. DOI: 10.1200/JCO.2008.17.7618.

6. Yardley D.A., Chandra P., Hart L. et al. A phase II randomized study with eribulin/ cyclophosphamide (ErC) and docetaxel/cyclophosphamide (TC) as neoadjuvant therapy in HER2-negative breast cancer – final analysis of primary endpoint and correlative analysis results. Cancer Res 2016;76(4 Suppl):P1-14-06. DOI: 10.1158/1538-7445.SABCS15-P1-14-06.

7. Burstein H.J., Weiner E.P. Primary care for survivors of breast cancer. N Engl J Med 2000;343(15):1086–94. DOI: 10.1056/NEJM200010123431506.

8. Greenlee R., Murray T., Bolden Sh. et al. Cancer statistics, 2000. Percentage distribution of cancer cases by race and stage at diagnosis: U.S., 1989–1995. CA Cancer J Clin 2000;50(1):7–33.

9. Tutt A., Ellis P., Kilburn L. et al. TNT: a randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple-negative or BRCA1/2 breast cancer. Cancer Res 2015;75(9 Suppl):S3-01. DOI: 10.1158/1538-7445.SABCS14-S3-01.

10. Carey L.A., Dees E.C., Sawyer L. et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13(8):2329–34. DOI: 10.1158/1078-0432.CCR-06-1109.

11. Liedtke C., Mazouni C., Hess K.R. et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26(8): 1275–81. DOI: 10.1200/JCO.2007.14.4147.

12. Wetterskog D., Lopez-Garcia M.A., Lambros M.B. et al. Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol 2012;226(1):84–96. DOI: 10.1002/path.2974.

13. Tognon C., Knezevich S.R., Huntsman D. et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002;2(5):367–76. PMID: 12450792.

14. Mayer I.A., Abramson V.G., Lehmann B.D. et al. New strategies for triple-negative breast cancer-deciphering the heterogeneity. Clin Cancer Res 2014;20(4):782–90. DOI: 10.1158/1078-0432.CCR-13-0583.

15. Masuda H., Baggerly K.A., Wang Y. et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013;19(19):5533–40. DOI: 10.1158/1078-0432.CCR-13-0799.

16. Lehmann B.D., Bauer J.A., Schafer J.M. et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res 2014;16(4):406. DOI: 10.1186/s13058-014-0406-x.

17. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10(2):116–29. DOI: 10.1038/nrc2780.

18. Turner N., Lambros M.B., Horlings H.M. et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010;29(14):2013–23. DOI: 10.1038/onc.2009.489.